CU20190078A7 - Péptidos útiles en el tratamiento de diabetes - Google Patents

Péptidos útiles en el tratamiento de diabetes

Info

Publication number
CU20190078A7
CU20190078A7 CU2019000078A CU20190078A CU20190078A7 CU 20190078 A7 CU20190078 A7 CU 20190078A7 CU 2019000078 A CU2019000078 A CU 2019000078A CU 20190078 A CU20190078 A CU 20190078A CU 20190078 A7 CU20190078 A7 CU 20190078A7
Authority
CU
Cuba
Prior art keywords
diabetes
treatment
useful peptides
peptides
useful
Prior art date
Application number
CU2019000078A
Other languages
English (en)
Other versions
CU24596B1 (es
Inventor
Vincent Carlier
Jean-Marie Saint-Remy
Elst Luc Vander
Original Assignee
Imcyse Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcyse Sa filed Critical Imcyse Sa
Publication of CU20190078A7 publication Critical patent/CU20190078A7/es
Publication of CU24596B1 publication Critical patent/CU24596B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)

Abstract

<p>La invención se refiere a péptidos tales como HCPYCSLQPLALEGSLQKRG, útiles en el tratamiento de diabetes tipo 1 y a la generación de célula T CD4+ citolítica.</p>
CU2019000078A 2017-03-09 2018-03-06 Péptidos obtenidos a partir de insulina útiles en el tratamiento de diabetes CU24596B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17160085 2017-03-09
PCT/EP2018/055501 WO2018162498A1 (en) 2017-03-09 2018-03-06 Peptides and methods for the treatment of diabetes

Publications (2)

Publication Number Publication Date
CU20190078A7 true CU20190078A7 (es) 2020-04-02
CU24596B1 CU24596B1 (es) 2022-05-11

Family

ID=58266442

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000078A CU24596B1 (es) 2017-03-09 2018-03-06 Péptidos obtenidos a partir de insulina útiles en el tratamiento de diabetes

Country Status (21)

Country Link
US (4) US10808016B2 (es)
EP (1) EP3592765A1 (es)
JP (2) JP7102430B2 (es)
KR (1) KR20190126798A (es)
CN (1) CN110536898B (es)
AU (2) AU2018229741B2 (es)
BR (1) BR112019018616A2 (es)
CA (1) CA3051518A1 (es)
CO (1) CO2019009080A2 (es)
CU (1) CU24596B1 (es)
IL (1) IL268874B2 (es)
MX (1) MX2019010558A (es)
MY (1) MY192295A (es)
NZ (1) NZ755744A (es)
PE (1) PE20191529A1 (es)
PH (1) PH12019502036A1 (es)
RU (1) RU2761653C2 (es)
SA (1) SA519410007B1 (es)
SG (1) SG11201908275XA (es)
WO (1) WO2018162498A1 (es)
ZA (1) ZA201905851B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008017517A1 (en) 2006-08-11 2008-02-14 Life Sciences Research Partners Vzw Immunogenic peptides and their use in immune disorders
ES2584430T3 (es) * 2008-02-14 2016-09-27 Life Sciences Research Partners Vzw Estrategias para prevenir y/o tratar las respuestas inmunitarias a los alofactores solubles
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
WO2018162498A1 (en) * 2017-03-09 2018-09-13 Imcyse Sa Peptides and methods for the treatment of diabetes
WO2021105371A1 (en) 2019-11-27 2021-06-03 Imcyse Sa Methods for stratifying diabetes patients
CA3182369A1 (en) * 2020-05-06 2021-07-22 Imcyse Sa Combination treatment for fumarate-related diseases
EP4146254A1 (en) 2020-05-06 2023-03-15 Imcyse SA Immunogenic peptides with extended oxidoreductase motifs
MX2023014318A (es) 2021-06-01 2024-01-25 Imcyse Sa Metodos de tratamiento mejorados utilizando peptidos inmunogenicos.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009508517A (ja) * 2005-09-22 2009-03-05 コーエン，イルン，アール Ｔ細胞受容体定常ドメインの免疫原性断片及びそれに由来するペプチド
WO2008017517A1 (en) 2006-08-11 2008-02-14 Life Sciences Research Partners Vzw Immunogenic peptides and their use in immune disorders
EP2719396B1 (en) 2008-02-14 2017-06-21 Life Sciences Research Partners VZW Immunotherapy targeting intracellular pathogens
EP2245059B1 (en) * 2008-02-14 2017-09-20 Life Sciences Research Partners VZW Cd4+ t-cells with cytolytic properties
ES2584430T3 (es) 2008-02-14 2016-09-27 Life Sciences Research Partners Vzw Estrategias para prevenir y/o tratar las respuestas inmunitarias a los alofactores solubles
WO2009100505A1 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Immunogenic peptides and their use in transplantati
WO2009101204A2 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Elimination of immune responses to viral vectors
US8999346B2 (en) 2008-02-14 2015-04-07 Life Sciences Research Partners Vzw Immunogenic control of tumours and tumour cells
AR081809A1 (es) 2010-03-29 2012-10-24 Inst Nat Sante Rech Med Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas
GB201201511D0 (en) * 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) * 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
SG10201803780UA (en) * 2013-11-04 2018-06-28 Uti Lp Methods and compositions for sustained immunotherapy
GB201418433D0 (en) * 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
WO2018162498A1 (en) 2017-03-09 2018-09-13 Imcyse Sa Peptides and methods for the treatment of diabetes
US20210401976A1 (en) * 2018-11-12 2021-12-30 Imcyse Sa Immunogenic peptides with improved oxidoreductase motifs
TWM593454U (zh) 2019-11-11 2020-04-11 競泰股份有限公司 多鑰匙鎖心

Also Published As

Publication number Publication date
BR112019018616A2 (pt) 2020-04-28
PH12019502036A1 (en) 2020-06-15
CN110536898B (zh) 2023-09-08
MX2019010558A (es) 2019-10-21
US10808016B2 (en) 2020-10-20
SA519410007B1 (ar) 2023-02-16
MY192295A (en) 2022-08-17
CA3051518A1 (en) 2018-09-13
KR20190126798A (ko) 2019-11-12
IL268874A (en) 2019-10-31
CU24596B1 (es) 2022-05-11
AU2018229741B2 (en) 2021-09-02
AU2021277735A1 (en) 2021-12-23
JP2020509067A (ja) 2020-03-26
RU2019126232A3 (es) 2021-06-01
JP7102430B2 (ja) 2022-07-19
RU2019126232A (ru) 2021-04-10
US20190352348A1 (en) 2019-11-21
US20200407406A1 (en) 2020-12-31
IL268874B1 (en) 2023-05-01
US11760782B2 (en) 2023-09-19
US11407795B2 (en) 2022-08-09
WO2018162498A1 (en) 2018-09-13
JP2022125216A (ja) 2022-08-26
EP3592765A1 (en) 2020-01-15
RU2761653C2 (ru) 2021-12-13
CO2019009080A2 (es) 2019-08-30
US20240092843A1 (en) 2024-03-21
US20220411476A1 (en) 2022-12-29
IL268874B2 (en) 2023-09-01
SG11201908275XA (en) 2019-10-30
AU2018229741A1 (en) 2019-08-15
ZA201905851B (en) 2021-04-28
CN110536898A (zh) 2019-12-03
PE20191529A1 (es) 2019-10-23
NZ755744A (en) 2023-07-28

Similar Documents

Publication Publication Date Title
CU20190078A7 (es) Péptidos útiles en el tratamiento de diabetes
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
PH12017502255A1 (en) Nrf2 regulators
MX371187B (es) Péptidos terapéuticos.
TW201614072A (en) CAR-T lymphocytes engineered to home to lymph node B cell zone, skin, or gastrointestinal tract
EA201592103A2 (ru) Способы и композиции для усиления cd4+ регуляторных t-клеток
PH12016501151A1 (en) Nrf2 regulators
NI201300143A (es) Coagonista del receptor de glucagón/glp-1
PE20160179A1 (es) Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metoxi)benzaldehido
BR112017010173A2 (pt) composição para tratamento de tecido
DOP2016000042A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
MA38860B1 (fr) Cellule progénitrice immuno-modulatrice (imp)
ES2693321T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
CY1124761T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
MX2022013454A (es) Moduladores de la actividad del complemento.
BR112017010177A2 (pt) composição para tratamento de tecido
EA201700136A1 (ru) Полимерная композиция для слоя элемента слоя
MX2018004121A (es) Receptores de antigeno y usos de los mismos.
EA201890439A1 (ru) ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА)
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
EP4295914A3 (en) Genetically-engineered drug resistant t cells and methods of using the same
SV2017005585A (es) Peptidos lipidados resistentes a proteasas
IN2014CH00151A (es)
MX2018016322A (es) Composiciones hidrolíticamente estables para láminas en células solares.
NZ717192A (en) Anti-inflammatory tripeptides